Current hormonal therapy for disseminated prostate cancer
https://doi.org/10.17650/1726-9776-2006-2-2-54-58
Abstract
Prostate cancer (PC) is one of the most common malignancies in males. Hormonal therapy (HT) is the method of choice in treating disseminated PC. LHRH agonists are used for therapy of disseminated and metastatic PC; a number of studies have shown the advantages of adjuvant and neoadjuvant HT for its locally advanced process over radiotherapy (RT) alone and radical prostatectomy (RPE). Diferelin (tryptorelin) that has been used for over 20 years is one of the most studied LHRH agonists. The efficiency of HT with diferelin is comparable with that of bilateral orchiectomy, the quality of life being much higher in the patients receiving this drug. The efficiency of intermittent diferelin HT is shown to be the same as that of continuous HT, by considerably improving the quality of life. Diferelin may be used for evaluation of the hormonal sensitivity of a tumor and for choice of an efficient treatment policy. Comparison of diferelin with other LHRH agonists has yielded comparable results in the trend of prostate-specific antigen levels and testosterone concentrations to decrease.
About the Authors
I. G. Rusakov
P.A. Herzen Moscow Cancer Research Institute
Russian Federation
Russian Federation
A. A. Bystrov
City Clinical Hospital No. 62, Moscow
Russian Federation
Russian Federation
F. R. Amosov
Moscow City Cancer Dispensary
Russian Federation
Russian Federation
References
1. Аксель Е.М. Эпидемиология рака предстательной железы. М., 2005.
2. Матвеев Б.П. Клиническая онкоурология. М.; 2003. с. 274–86.
3. Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941: 63.
4. Bayar D.P. Studies on prostate cancer and its treatment. 1977. p. 164.
5. Daneshgari F., Crawford E.D. Endocrine therapy of advanced prostate cancer. Cancer 1993; 71 (3 Suppl): 1089—97.
6. Kaisary A.V., Tyrrell C.J., Peeling W.B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991; 67(5): 502–8.
7. Labrie F., Belanger A., Dupont A. et al. Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med 1993;16(6):475–92.
8. Teillac P., Heyns C.F., Kaisary A.V. et al. Pharmacodynamic equivalence of a decapeptyl 3-month SR formulation with the 28-day SR formulation in patients with advanced prostate cancer. Horm Res 2004;62(5):252–8. Epub 2004 Oct 19.
9. Bolla M., Collette L., Blank L. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360(9327): 103–6.
10. Bolla M., Maingon P., Fourneret P. et al. Indications of the association of radiotherapy and hormonal treatment in prostate cancer. Cancer Radiother 2005; 9(6–7): 394–8. Epub 2005 Oct 11.
11. Bolla M. Does adjuvant androgen suppression after radiotherapy for prostate cancer improve long-term outcomes? Natl Clin Pract Urol 2005;2(11):536–7.
12. Lawton C.A., Winter K., Murray K. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85—31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49(4):937–46.
13. Messing E.M. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003; 170(5): 1955–6.
14. Pilepich M.V., Winter K., John M.J. et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50(5):1243–52.
15. Pilepich M.V., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61(5):1285–90.
16. Русаков И.Г, Амосов Ф.Р., Быстров А.А. Место диферелина в лечении распространенного рака предстательной железы. Фарматека 2004;18:102–7.
17. Kuhn J.M., Abourachid H., Brucher P. et al. Randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. Eur Urol 1997;32(4):397–403.
18. Abbou C.C., Lucas C., Leblanc V. Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer. Prog Urol 1997;7(6):984–95.
19. Heyns C.F., Simonin M.P., Grosgurin P. et al. For the South African Triptorelin Study Group. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int 2003; 92(3):226–31.
20. Messing E.M., Thompson I. Jr. Follow-up of conservatively managed prostate cancer: watchful waiting and primary hormonal therapy. Urol Clin North Am 2003; 30(4):687–702.
21. Roach M. 3rd, Lu J., Pilepich M.V. et al. Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 2000;47(3):617–27.
22. Shipley W.U., Lu J.D., Pilepich M.V. et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. Int J Radiat Oncol Biol Phys 2002;54(5):1302–10.
Review
For citations:
Rusakov I.G., Bystrov A.A., Amosov F.R. Current hormonal therapy for disseminated prostate cancer. Cancer Urology. 2006;2(2):54-58. (In Russ.) https://doi.org/10.17650/1726-9776-2006-2-2-54-58
Views:
208
Email this article 